Antiviral Protection by IFITM3 In Vivo

Current Clinical Microbiology Reports

Volumn 5, Issue 4, 2018, Pages 229-237

  Zani, Ashley ^a   Yount, Jacob S ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

IFITM; Interferon; ISG; rs12252; rs34481144; Virus

Indexed keywords

EID: 85054793381     PISSN: None     EISSN: 21965471     Source Type: Journal    
DOI: 10.1007/s40588-018-0103-0     Document Type: Review

References (75)

1. Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM, et al. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell. 2009;139(7):1243–54. 10.1016/j.cell.2009.12.017.
2. Yount JS, Moltedo B, Yang YY, Charron G, Moran TM, Lopez CB, et al. Palmitoylome profiling reveals S-palmitoylation-dependent antiviral activity of IFITM3. Nat Chem Biol. 2010;6(8):610–4. 10.1038/nchembio.405.
3. Feeley EM, Sims JS, John SP, Chin CR, Pertel T, Chen LM, et al. IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog. 2011;7(10):e1002337. 10.1371/journal.ppat.1002337.
4. Desai TM, Marin M, Chin CR, Savidis G, Brass AL, Melikyan GB. IFITM3 restricts influenza A virus entry by blocking the formation of fusion pores following virus-endosome hemifusion. PLoS Pathog. 2014;10(4):e1004048. 10.1371/journal.ppat.1004048.
5. Li K, Markosyan RM, Zheng YM, Golfetto O, Bungart B, Li M, et al. IFITM proteins restrict viral membrane hemifusion. PLoS Pathog. 2013;9(1):e1003124. 10.1371/journal.ppat.1003124.
6. Friedman RL, Manly SP, McMahon M, Kerr IM, Stark GR. Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells. Cell. 1984;38(3):745–55.
7. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011;472(7344):481–5. 10.1038/nature09907.
8. Lu J, Pan Q, Rong L, He W, Liu SL, Liang C. The IFITM proteins inhibit HIV-1 infection. J Virol. 2011;85(5):2126–37. 10.1128/JVI.01531-10.
9. Weidner JM, Jiang D, Pan XB, Chang J, Block TM, Guo JT. Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J Virol. 2010;84(24):12646–57. 10.1128/JVI.01328-10.
10. John SP, Chin CR, Perreira JM, Feeley EM, Aker AM, Savidis G, et al. The CD225 domain of IFITM3 is required for both IFITM protein association and inhibition of influenza A virus and dengue virus replication. J Virol. 2013;87(14):7837–52. 10.1128/JVI.00481-13.
11. Yount JS, Karssemeijer RA, Hang HC. S-palmitoylation and ubiquitination differentially regulate interferon-induced transmembrane protein 3 (IFITM3)-mediated resistance to influenza virus. J Biol Chem. 2012;287(23):19631–41. 10.1074/jbc.M112.362095.
12. Hach JC, McMichael T, Chesarino NM, Yount JS. Palmitoylation on conserved and nonconserved cysteines of murine IFITM1 regulates its stability and anti-influenza A virus activity. J Virol. 2013;87(17):9923–7. 10.1128/JVI.00621-13.
13. McMichael TM, Zhang L, Chemudupati M, Hach JC, Kenney AD, Hang HC, et al. The palmitoyltransferase ZDHHC20 enhances interferon-induced transmembrane protein 3 (IFITM3) palmitoylation and antiviral activity. J Biol Chem. 2017;292(52):21517–26. 10.1074/jbc.M117.800482.
14. Huang IC, Bailey CC, Weyer JL, Radoshitzky SR, Becker MM, Chiang JJ, et al. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog. 2011;7(1):e1001258. 10.1371/journal.ppat.1001258.
15. Almen MS, Bringeland N, Fredriksson R, Schioth HB. The Dispanins: a novel gene family of ancient origin that contains 14 human members. Plos One. 2012;7(2). 10.1371/journal.pone.0031961.
16. Melvin WJ, McMichael TM, Chesarino NM, Hach JC, Yount JS. IFITMs from mycobacteria confer resistance to influenza virus when expressed in human cells. Viruses. 2015;7(6):3035–52. 10.3390/v7062759.
17. Zhang Z, Liu J, Li M, Yang H, Zhang C. Evolutionary dynamics of the interferon-induced transmembrane gene family in vertebrates. PLoS One. 2012;7(11):e49265. 10.1371/journal.pone.0049265.
18. Compton AA, Roy N, Porrot F, Billet A, Casartelli N, Yount JS, et al. Natural mutations in IFITM3 modulate post-translational regulation and toggle antiviral specificity. EMBO Rep. 2016;17(11):1657–71. 10.15252/embr.201642771.
19. Perreira JM, Chin CR, Feeley EM, Brass AL. IFITMs restrict the replication of multiple pathogenic viruses. J Mol Biol. 2013;425(24):4937–55. 10.1016/j.jmb.2013.09.024.
20. Smith S, Weston S, Kellam P, Marsh M. IFITM proteins-cellular inhibitors of viral entry. Curr Opin Virol. 2014;4:71–7. 10.1016/j.coviro.2013.11.004.
21. Jia R, Xu F, Qian J, Yao Y, Miao C, Zheng YM, et al. Identification of an endocytic signal essential for the antiviral action of IFITM3. Cell Microbiol. 2014;16(7):1080–93. 10.1111/cmi.12262.
22. McMichael TM, Zhang Y, Kenney AD, Zhang L, Lu M, Chemudupati M et al. Opposing roles of endosomal innate immunity proteins IFITM3 and TLR7 in human metapneumovirus infection. bioRxiv. 2018. 10.1101/290957.
23. Chesarino NM, McMichael TM, Yount JS. Regulation of the trafficking and antiviral activity of IFITM3 by post-translational modifications. Future Microbiol. 2014;9(10):1151–63. 10.2217/fmb.14.65.
24. Jia R, Pan Q, Ding S, Rong L, Liu SL, Geng Y, et al. The N-terminal region of IFITM3 modulates its antiviral activity by regulating IFITM3 cellular localization. J Virol. 2012;86(24):13697–707. 10.1128/JVI.01828-12.
25. Chesarino NM, McMichael TM, Hach JC, Yount JS. Phosphorylation of the antiviral protein interferon-inducible transmembrane protein 3 (IFITM3) dually regulates its endocytosis and ubiquitination. J Biol Chem. 2014;289(17):11986–92. 10.1074/jbc.M114.557694.
26. Shan Z, Han Q, Nie J, Cao X, Chen Z, Yin S, et al. Negative regulation of interferon-induced transmembrane protein 3 by SET7-mediated lysine monomethylation. J Biol Chem. 2013;288(49):35093–103. 10.1074/jbc.M113.511949.
27. Shan J, Zhao B, Shan Z, Nie J, Deng R, Xiong R, et al. Histone demethylase LSD1 restricts influenza A virus infection by erasing IFITM3-K88 monomethylation. PLoS Pathog. 2017;13(12):e1006773. 10.1371/journal.ppat.1006773.
28. Chesarino NM, McMichael TM, Yount JS. E3 ubiquitin ligase NEDD4 promotes influenza virus infection by decreasing levels of the antiviral protein IFITM3. PLoS Pathog. 2015;11(8):e1005095. 10.1371/journal.ppat.1005095.
29. Yount JS, Zhang MM, Hang HC. Emerging roles for protein S-palmitoylation in immunity from chemical proteomics. Curr Opin Chem Biol. 2013;17(1):27–33. 10.1016/j.cbpa.2012.11.008.
30. Yount JS, Charron G, Hang HC. Bioorthogonal proteomics of 15-hexadecynyloxyacetic acid chemical reporter reveals preferential targeting of fatty acid modified proteins and biosynthetic enzymes. Bioorg Med Chem. 2012;20(2):650–4. 10.1016/j.bmc.2011.03.062.
31. Chesarino NM, Hach JC, Chen JL, Zaro BW, Rajaram MV, Turner J, et al. Chemoproteomics reveals toll-like receptor fatty acylation. BMC Biol. 2014;12:91. 10.1186/s12915-014-0091-3.
32. Percher A, Ramakrishnan S, Thinon E, Yuan X, Yount JS, Hang HC. Mass-tag labeling reveals site-specific and endogenous levels of protein S-fatty acylation. Proc Natl Acad Sci U S A. 2016;113(16):4302–7. 10.1073/pnas.1602244113.
33. • Chesarino NM, Compton AA, McMichael TM, Kenney AD, Zhang L, Soewarna V, et al. IFITM3 requires an amphipathic helix for antiviral activity. EMBO Rep. 2017;18(10):1740–51. 10.15252/embr.201744100. This study identifies a short, highly conserved amphipathic helix within the IFITM3 amino acid sequence as a structural element required for inhibition of virus membrane fusion. The proximity of this helix to critical S-palmitoylation sites suggests that this modification may be involved in membrane anchoring of the helix. Further, the known function of amphipathic helices in inducing membrane curvature provides a new mechanistic model for inhibition of virus infections by IFITM3.
34. Shi G, Schwartz O, Compton AA. More than meets the I: the diverse antiviral and cellular functions of interferon-induced transmembrane proteins. Retrovirology. 2017;14(1):53. 10.1186/s12977-017-0377-y.
35. Tartour K, Appourchaux R, Gaillard J, Nguyen XN, Durand S, Turpin J, et al. IFITM proteins are incorporated onto HIV-1 virion particles and negatively imprint their infectivity. Retrovirology. 2014;11:103. 10.1186/s12977-014-0103-y.
36. Compton AA, Bruel T, Porrot F, Mallet A, Sachse M, Euvrard M, et al. IFITM proteins incorporated into HIV-1 virions impair viral fusion and spread. Cell Host Microbe. 2014;16(6):736–47. 10.1016/j.chom.2014.11.001.
37. Tartour K, Nguyen XN, Appourchaux R, Assil S, Barateau V, Bloyet LM, et al. Interference with the production of infectious viral particles and bimodal inhibition of replication are broadly conserved antiviral properties of IFITMs. PLoS Pathog. 2017;13(9):e1006610. 10.1371/journal.ppat.1006610.
38. Lange UC, Adams DJ, Lee C, Barton S, Schneider R, Bradley A, et al. Normal germ line establishment in mice carrying a deletion of the Ifitm/Fragilis gene family cluster. Mol Cell Biol. 2008;28(15):4688–96. 10.1128/MCB.00272-08.
39. Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, et al. IFITM3 restricts the morbidity and mortality associated with influenza. Nature. 2012;484(7395):519–23. 10.1038/nature10921.
40. Bailey CC, Huang IC, Kam C, Farzan M. Ifitm3 limits the severity of acute influenza in mice. PLoS Pathog. 2012;8(9):e1002909. 10.1371/journal.ppat.1002909.
41. • Poddar S, Hyde JL, Gorman MJ, Farzan M, Diamond MS. The interferon-stimulated gene IFITM3 restricts infection and pathogenesis of arthritogenic and encephalitic alphaviruses. J Virol. 2016;90(19):8780–94. 10.1128/JVI.00655-16. This study demonstrates that alphavirus infections induce more severe pathologies in IFITM3 KO mice than in WT mice. The work extends the known range of pathogens restricted by IFITM3 in vivo.
42. Gorman MJ, Poddar S, Farzan M, Diamond MS. The interferon-stimulated gene Ifitm3 restricts West Nile virus infection and pathogenesis. J Virol. 2016;90(18):8212–25. 10.1128/JVI.00581-16.
43. • Stacey MA, Clare S, Clement M, Marsden M, Abdul-Karim J, Kane L, et al. The antiviral restriction factor IFN-induced transmembrane protein 3 prevents cytokine-driven CMV pathogenesis. J Clin Invest. 2017;127(4):1463–74. 10.1172/JCI84889. This study shows that IFITM3 KO mice experience more severe pathologies than WT mice in cytomegalovirus infections. This is the first work to suggest that IFITM3 plays a role beyond direct virus restriction in vivo since cytomegalovirus infection of cells is not inhibited by IFITM3. The authors provide evidence that their observed effects are due to overproduction of IL-6 in IFITM3 KO mice.
44. Zhang W, Zhang L, Zan YL, Du N, Yang Y, Tien P. Human respiratory syncytial virus infection is inhibited by IFN-induced transmembrane proteins. J Gen Virol. 2015;96:170–82. 10.1099/vir.0.066555-0.
45. Everitt AR, Clare S, McDonald JU, Kane L, Harcourt K, Ahras M, et al. Defining the range of pathogens susceptible to Ifitm3 restriction using a knockout mouse model. PLoS One. 2013;8(11):e80723. 10.1371/journal.pone.0080723.
46. Infusini G, Smith JM, Yuan H, Pizzolla A, Ng WC, Londrigan SL, et al. Respiratory DC use IFITM3 to avoid direct viral infection and safeguard virus-specific CD8+ T cell priming. PLoS One. 2015;10(11):e0143539. 10.1371/journal.pone.0143539.
47. Wakim LM, Gupta N, Mintern JD, Villadangos JA. Enhanced survival of lung tissue-resident memory CD8(+) T cells during infection with influenza virus due to selective expression of IFITM3. Nat Immunol. 2013;14(3):238–45. 10.1038/ni.2525.
48. Savidis G, Perreira JM, Portmann JM, Meraner P, Guo Z, Green S, et al. The IFITMs inhibit Zika virus replication. Cell Rep. 2016;15(11):2323–30. 10.1016/j.celrep.2016.05.074.
49. Narayana SK, Helbig KJ, McCartney EM, Eyre NS, Bull RA, Eltahla A, et al. The interferon-induced transmembrane proteins, IFITM1, IFITM2, and IFITM3 inhibit hepatitis C virus entry. J Biol Chem. 2015;290(43):25946–59. 10.1074/jbc.M115.657346.
50. Yao L, Dong H, Zhu H, Nelson D, Liu C, Lambiase L, et al. Identification of the IFITM3 gene as an inhibitor of hepatitis C viral translation in a stable STAT1 cell line. J Viral Hepat. 2011;18(10):e523–9. 10.1111/j.1365-2893.2011.01452.x.
51. Monel B, Compton AA, Bruel T, Amraoui S, Burlaud-Gaillard J, Roy N, et al. Zika virus induces massive cytoplasmic vacuolization and paraptosis-like death in infected cells. EMBO J. 2017;36(12):1653–68. 10.15252/embj.201695597.
52. Pan Y, Yang P, Dong T, Zhang Y, Shi W, Peng X, et al. IFITM3 Rs12252-C variant increases potential risk for severe influenza virus infection in Chinese population. Front Cell Infect Microbiol. 2017;7:294. 10.3389/fcimb.2017.00294.
53. Lee N, Cao B, Ke C, Lu H, Hu Y, Tam CHT, et al. IFITM3, TLR3, and CD55 gene SNPs and cumulative genetic risks for severe outcomes in Chinese patients with H7N9/H1N1pdm09 influenza. J Infect Dis. 2017;216(1):97–104. 10.1093/infdis/jix235.
54. Wang Z, Zhang A, Wan Y, Liu X, Qiu C, Xi X, et al. Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. Proc Natl Acad Sci U S A. 2014;111(2):769–74. 10.1073/pnas.1321748111.
55. Zhang YH, Zhao Y, Li N, Peng YC, Giannoulatou E, Jin RH, et al. Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals. Nat Commun. 2013;4:1418. 10.1038/ncomms2433.
56. Mehrbod P, Eybpoosh S, Fotouhi F, Shokouhi Targhi H, Mazaheri V, Farahmand B. Association of IFITM3 rs12252 polymorphisms, BMI, diabetes, and hypercholesterolemia with mild flu in an Iranian population. Virol J. 2017;14(1):218. 10.1186/s12985-017-0884-4.
57. Mills TC, Rautanen A, Elliott KS, Parks T, Naranbhai V, Ieven MM, et al. IFITM3 and susceptibility to respiratory viral infections in the community. J Infect Dis. 2014;209(7):1028–31. 10.1093/infdis/jit468.
58. Randolph AG, Yip WK, Allen EK, Rosenberger CM, Agan AA, Ash SA, et al. Evaluation of IFITM3 rs12252 association with severe pediatric influenza infection. J Infect Dis. 2017;216(1):14–21. 10.1093/infdis/jix242.
59. Carter TC, Hebbring SJ, Liu J, Mosley JD, Shaffer CM, Ivacic LC, et al. Pilot screening study of targeted genetic polymorphisms for association with seasonal influenza hospital admission. J Med Virol. 2018;90(3):436–46. 10.1002/jmv.24975.
60. Lopez-Rodriguez M, Herrera-Ramos E, Sole-Violan J, Ruiz-Hernandez JJ, Borderias L, Horcajada JP, et al. IFITM3 and severe influenza virus infection. No evidence of genetic association. Eur J Clin Microbiol Infect Dis. 2016;35(11):1811–7. 10.1007/s10096-016-2732-7.
61. Gaio V, Nunes B, Pechirra P, Conde P, Guiomar R, Dias CM, et al. Hospitalization risk due to respiratory illness associated with genetic variation at IFITM3 in patients with influenza A(H1N1)pdm09 infection: a case-control study. PLoS One. 2016;11(6):e0158181. 10.1371/journal.pone.0158181.
62. David S, Correia V, Antunes L, Faria R, Ferrao J, Faustino P, et al. Population genetics of IFITM3 in Portugal and Central Africa reveals a potential modifier of influenza severity. Immunogenetics. 2017;70:169–77. 10.1007/s00251-017-1026-2.
63. Xu-Yang Z, Pei-Yu B, Chuan-Tao Y, Wei Y, Hong-Wei M, Kang T, et al. Interferon-induced transmembrane protein 3 inhibits Hantaan virus infection, and its single nucleotide polymorphism rs12252 influences the severity of hemorrhagic fever with renal syndrome. Front Immunol. 2016;7:535. 10.3389/fimmu.2016.00535.
64. Zhang YH, Makvandi-Nejad S, Qin L, Zhao Y, Zhang T, Wang LL, et al. Interferon-induced transmembrane protein-3 rs12252-C is associated with rapid progression of acute HIV-1 infection in Chinese MSM cohort. AIDS. 2015;29(8):889–94. 10.1097/Qad.0000000000000632.
65. •• Allen EK, Randolph AG, Bhangale T, Dogra P, Ohlson M, Oshansky CM, et al. SNP-mediated disruption of CTCF binding at the IFITM3 promoter is associated with risk of severe influenza in humans. Nat Med. 2017;23(8):975–83. 10.1038/nm.4370. This study identifies a new SNP in the IFITM3 gene, rs34411844-A, associated with severe influenza virus infections in humans. This SNP correlates with decreased IFITM3 protein and mRNA levels.
66. • Makvandi-Nejad S, Laurenson-Schafer H, Wang L, Wellington D, Zhao Y, Jin B, et al. Lack of truncated IFITM3 transcripts in cells homozygous for the rs12252-C variant that is associated with severe influenza infection. J Infect Dis. 2018;217(2):257–62. 10.1093/infdis/jix512. This study provides evidence that refutes the predominant hypothesis in the IFITM3 literature that the rs12252-C polymorphism alters IFITM3 splicing. Alternatively, spliced transcripts were not detected via RNA sequencing.
67. Kenney AD, Dowdle JA, Bozzacco L, McMichael TM, St Gelais C, Panfil AR, et al. Human genetic determinants of viral diseases. Annu Rev Genet. 2017;51:241–63. 10.1146/annurev-genet-120116-023425.
68. Jiang LQ, Xia T, Hu YH, Sun MS, Yan S, Lei CQ, et al. IFITM3 inhibits virus-triggered induction of type I interferon by mediating autophagosome-dependent degradation of IRF3. Cell Mol Immunol. 2017; 10.1038/cmi.2017.15.
69. Lin TY, Chin CR, Everitt AR, Clare S, Perreira JM, Savidis G, et al. Amphotericin B increases influenza A virus infection by preventing IFITM3-mediated restriction. Cell Rep. 2013;5(4):895–908. 10.1016/j.celrep.2013.10.033.
70. Daugherty MD, Malik HS. Rules of engagement: molecular insights from host-virus arms races. Annu Rev Genet. 2012;46:677–700. 10.1146/annurev-genet-110711-155522.
71. Sun X, Zeng H, Kumar A, Belser JA, Maines TR, Tumpey TM. Constitutively expressed IFITM3 protein in human endothelial cells poses an early infection block to human influenza viruses. J Virol. 2016;90(24):11157–67. 10.1128/JVI.01254-16.
72. Gerlach T, Hensen L, Matrosovich T, Bergmann J, Winkler M, Peteranderl C, et al. pH optimum of hemagglutinin-mediated membrane fusion determines sensitivity of influenza A viruses to the interferon-induced antiviral state and IFITMs. J Virol. 2017;91(11) 10.1128/JVI.00246-17.
73. Ding S, Pan Q, Liu SL, Liang C. HIV-1 mutates to evade IFITM1 restriction. Virology. 2014;454–455:11–24. 10.1016/j.virol.2014.01.020.
74. •• Foster TL, Wilson H, Iyer SS, Coss K, Doores K, Smith S, et al. Resistance of transmitted founder HIV-1 to IFITM-mediated restriction. Cell Host Microbe. 2016;20(4):429–42. 10.1016/j.chom.2016.08.006. This study suggests that HIV-1 evolves to evade restriction by IFITMs in humans. They provide evidence that transmitted founder viruses are resistant to IFITMs and that susceptibility to IFITMs increases as the virus mutates to evade adaptive immune mechanisms, such as antibodies.
75. Wang Y, Pan Q, Ding S, Wang Z, Yu J, Finzi A, et al. The V3 Loop of HIV-1 Env Determines Viral Susceptibility to IFITM3 Impairment of Viral Infectivity. J Virol. 2017;91(7) 10.1128/JVI.02441-16.